Patients and Study Design
UC
Data were pooled from OCTAVE Induction 1 and 2, two randomized, double-blind, placebo-controlled, identically designed induction studies of tofacitinib in adult patients with moderate to severe UC [The total Mayo score was determined at baseline and following 8 weeks of treatment [The SF-36 (version 2) was self-administered by patients at baseline and at week 8 [The IBDQ was the least time-consuming HRQoL measure used in the OCTAVE studies. IBDQ scores were measured at an additional timepoint as the questionnaire is shorter than the SF-36 and also self-administered, therefore minimizing the patient burden [